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BACKGROUND: Panitumumabþbest supportive care (BSC) significantly improved progression-free survival (PFS) vs BSC alone in
patients with chemo-refractory wild-type KRAS metastatic colorectal cancer (mCRC). We applied the quality-adjusted time without
symptoms of disease or toxicity (Q-TWiST) analysis to provide an integrated measure of clinical benefit, with the objective of
comparing quality-adjusted survival between the two arms. As the trial design allowed patients on BSC alone to receive panitumumab
after disease progression, which confounded overall survival (OS), the focus of this analysis was on PFS.
METHODS: For each treatment group, the time spent in the toxicity (grade 3 or 4 adverse events; TOX), time without symptoms of
disease or toxicity (TWiST), and relapse (after disease progression; REL) states were estimated by the product-limit method, and
adjusted using utility weights derived from patient-reported EuroQoL 5-dimensions measures. Sensitivity analyses were performed in
which utility weights (varying from 0 to 1) were applied to time in the TOX and REL health states.
RESULTS: There was a significant difference between groups favouring panitumumabþBSC in quality-adjusted PFS (12.3 weeks vs
5.8 weeks, respectively, Po0.0001) and quality-adjusted OS (P¼0.0303).
CONCLUSION: In patients with chemo-refractory wild-type KRAS mCRC, panitumumabþBSC significantly improved quality-adjusted
survival compared with BSC alone.
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Despite significant improvements in recent years, the treatment of
metastatic colorectal cancer (mCRC) for the vast majority of
patients is rarely curative, and thus the aims of treatment in this
setting extend beyond prolongation of survival to include the
improvement of tumour-related symptoms, prevention of tumour
progression and/or maintenance of quality of life (Van Cutsem
et al, 2010). Analyses of clinical trials for mCRC, however, typically
focus on efficacy and safety outcomes independently, which can
complicate the quantitative evaluation of the overall benefits of
treatment. Panitumumab, a fully human monoclonal antibody
directed against the epidermal growth factor receptor (EGFR), has
been shown to delay disease progression in combination with best
supportive care (BSC) compared with BSC alone in patients with
chemo-refractory wild-type KRAS mCRC (Amado et al, 2008).
However, similar to other monoclonal antibodies used in cancer
therapy, panitumumab is also associated with a well-defined
adverse event (AE) profile: in particular, skin toxicity, a well-
known side effect of anti-EGFR monoclonal antibodies, is observed
in up to 90% of patients (Van Cutsem et al, 2007).
The quality-adjusted time without symptoms of disease or
toxicity of treatment (Q-TWiST) analysis reflects that cancer
therapy is frequently associated with toxicities that may reduce the
benefits of increased survival (Miyamoto and Eraker, 1985;
Goldhirsch et al, 1989; Glasziou et al, 1990; Cole et al, 1994;
Miyamoto, 1999). Quality-adjusted time without symptoms of
disease or toxicity incorporates progression, survival, treatment
toxicities and utility measures into a single metric providing an
integrated measure of clinical benefit. The analysis is usually
applied to overall survival (OS) data obtained from clinical trials
(Goldhirsch et al, 1989). However, in the phase 3 trial of
panitumumab in chemo-refractory mCRC, patients in the BSC
alone arm were allowed to cross over to receive panitumumab after
disease progression. Overall, cross-over to panitumumab occurred
in 76% of patients in the BSC alone arm, and this confounded the
OS data from the study (Van Cutsem et al, 2007, 2010; Amado et al,
2008). Progression-free survival (PFS) was the primary end point
of the phase 3 trial. In order to better characterise the clinical
benefits of panitumumab in mCRC, we, therefore, performed a
Q-TWiST analysis to compare quality-adjusted survival among
subjects with chemo-refractory wild-type KRAS mCRC receiving
panitumumabþBSC with that of BSC alone, with a focus on the
PFS as OS was confounded by the cross-over study design.
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Data source
This Q-TWiST analysis was performed using PFS and OS data
from patients with wild-type KRAS tumours collected during the
phase 3, open-label, randomised, controlled study comparing the
use of panitumumabþBSC with BSC alone in patients with
chemo-refractory mCRC. The patient population and design for
this trial have been described elsewhere (Van Cutsem et al, 2007;
Amado et al, 2008). Briefly, patients with EGFR-detectable mCRC
and documented evidence of disease progression after failure of
fluoropyrimidines and prespecified exposure to oxaliplatin and
irinotecan were randomly assigned to receive panitumumab
6mgkg
 1þBSC every 2 weeks or BSC alone until disease
progression, inability to tolerate the investigational product or
discontinuation for other reasons. Patients in the BSC alone arm
could receive panitumumab after disease progression.
The primary end point of the study was PFS, with progression
assessed by central radiologic review (not by investigator’s
evaluation) at specified time points from weeks 8 to 48 using
Response Evaluation Criteria in Solid Tumours (RECIST), then
every 3 months thereafter. Overall survival was a secondary end
point. All subjects continued to be followed for survival approxi-
mately every 3 months for up to 2 years after their randomisation
into the study. Safety was assessed every 2 weeks and at a 30-day
follow-up visit. Health-related quality of life was reported by
patients at baseline and monthly until disease progression using the
EuroQoL 5-dimensions (EQ-5D) index (Shaw et al,2 0 0 5 ;O d o m
et al, 2011). The EQ-5D index provides a utility score.
Definitions
Overall survival for each treatment group was partitioned into
three health states: toxicity (TOX), time without symptoms of
disease or toxicity (TWiST) and relapse (disease progression; REL)
(Gelber and Goldhirsch, 1986; Goldhirsch et al, 1989). Toxicity was
defined as the time spent with grade 3 or 4 AEs prior to disease
progression. Per convention, AEs occurring after disease progres-
sion were not included in the TOX state. The calculation of TOX
was based on all grade 3 or 4 AEs reported in the trial. Each AE had
a start date and the end date was when the AE was resolved;
otherwise, the end date was truncated at disease progression. A day
with multiple AEs was only counted once. The duration of TOX
included the total number of days spent with AEs from
randomisation to disease progression. Time without symptoms
of disease or toxicity was defined as the remaining time prior to
disease progression in which no grade 3 or 4 AEs were
experienced. The end of the TWiST period was the earliest date
of disease progression or death and was censored at the date of the
last evaluable disease assessment. For subjects who withdrew
because of disease progression that was not confirmed by the
Independent Review Committee, radiographic data collected
during long-term follow-up was used in the primary analysis of
PFS. Relapse (disease progression) was defined as the period
following disease progression until death or end of follow-up. This
means that for patients in the BSC alone group who crossed over to
receive panitumumab after disease progression, any time spent
with grade 3 or 4 AEs associated with panitumumab treatment was
included in the REL period of the BSC alone arm.
To conduct the Q-TWiST analyses, the patient-reported health
status directly assessed in the study with the EQ-5D was used to
derive patient-reported utility weights, a method that has been
previously reported in the published literature (Bernhard et al,
2004; Zbrozek et al, 2010). For each patient, EQ-5D assessments
were averaged during the following periods: when the patient was
experiencing an AE (during TOX); prior to disease progression
without AEs (during TWiST) and on or after the date of disease
progression (during REL). Specifically, if a patient was experien-
cing a grade 3 or 4 AE during their monthly visit when EQ-5D was
assessed, then the EQ-5D score for that visit was used to derive the
utility weights for the TOX period. The available EQ-5D scores for
the TOX, TWiST and REL states were then averaged for each
treatment arm and used as utility scores in the Q-TWiST
calculation. As Q-TWiST analyses often use a range of hypothetical
utility values to generate quality-adjusted states (Gelber et al, 1996;
Irish et al, 2005; Konski et al, 2009), a sensitivity analysis using
hypothetical utility values was also performed.
Statistical analysis
Estimation of health state durations The product-limit method
(Kaplan and Meier, 1958) was used to estimate the mean amount of
time in the following states: time with any toxicity after randomi-
sation but prior to progression (i.e., TOX); time from randomisa-
tion to progression or death (i.e., PFS) and time from randomisation
until death from any cause (i.e., OS). Survival curves that
corresponded to TOX, PFS and OS were plotted on the same
graph for each treatment group. The areas between the curves
represented the restricted mean durations of TWiST and REL
as follows:
Durationof TWiST ¼ meanPFS   meantimewithtoxicities
Durationof REL ¼ meanOS   meanPFS
Calculation of Q-TWiST The mean Q-TWiST for each treatment
arm was calculated using the following formulae:
Q-TWiST ¼ðuTOX TOXÞþð uTWiST TWiSTÞ
þð uREL RELÞ
where uTOX, uTWiST and uREL represented the average group utility
values for each health state and TOX, TWiST and REL represented
the mean duration of the health states. The Q-TWiST scores for
each treatment group portrayed the quality-adjusted survival
experienced by patients during this study. Obviously, TOX and
TWiST together represent the PFS and Q-TWiST analysis becomes
the quality-adjusted PFS analysis in the case when the utility for
the period of REL (i.e., uREl) is set to zero. Differences between
treatment groups (panitumumabþBSC vs BSC alone) in mean
Q-TWiST were calculated. A 95% confidence interval (CI) and two-
sided P-value for testing the null hypothesis of no difference
between treatment groups was performed based on the normal
approximation (Z-test) with standard errors calculated by the
bootstrap method. The bootstrap was conducted by repeated
sampling, with replacement, from the sample of patients included
in the study, to obtain a new sample. The means for the new
sample were calculated from the area under the Kaplan–Meier
curve. This process was repeated 1000 times. Based on the means
obtained by the bootstrap, the standard errors were calculated
(Glasziou et al, 1990).
Sensitivity analysis Sensitivity analyses were performed based on
the threshold utility analyses, in which utility weights (varying
from 0 to 1) were applied to time in the TOX and REL health states,
while holding the utility of TWiST at 1 (representing the highest
utility that can be expected for a patient with mCRC) (Goldhirsch
et al, 1989; Gelber et al, 1995b; Cole et al, 1996). All analyses were
performed using SAS statistical software Version 9.1.3 (SAS, Cary,
NC, USA).
RESULTS
The intention to treat population included 463 patients (Van
Cutsem et al, 2007). KRAS status was ascertained in 427 (92%) of
Q-TWiST analysis of panitumumab in metastatic CRC
J Wang et al
1849
British Journal of Cancer (2011) 104(12), 1848–1853 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spatients. Of these, 243 patients had wild-type KRAS tumours
(panitumumabþBSC, n¼124; BSC alone, n¼119) and were
included in the Q-TWiST analyses. Baseline demographics of these
patients have been described elsewhere and were well balanced
between groups: median age was 63 years and 69% of patients had
colon rather than rectal cancer in both groups (Amado et al, 2008).
A total of 54% (67 out of 124) of panitumumabþBSC patients and
27% (32 out of 119) of BSC alone patients experienced a Xgrade 3
AE prior to progression or censoring for progression. Of the 119
BSC alone patients, 90 (76%) went on to receive panitumumab
after disease progression and 20 had a complete or partial response
during panitumumab treatment (Amado et al, 2008).
Patient-reported utility data
Observed utility data for each health state based on the EQ-5D
index are shown in Table 1. Ninety-three per cent (225 out of 243)
of patients completed at least one EQ-5D assessment. The average
utility value observed during the TOX state (Xgrade 3 AE) was
0.60 for the panitumumabþBSC group and 0.44 for the BSC alone
group. The average utility for the TWiST state was higher for the
panitumumabþBSC group compared with BSC alone (0.76 vs 0.66,
respectively), while utility values were similar in the two groups for
the REL state.
Health state durations
Partitioned survival plots for panitumumabþBSC and BSC alone,
restricted to median follow-up, are presented in Figure 1, with the
estimated mean duration of each health state shown in Table 2.
The mean duration in the TOX state was approximately 3.5 weeks
in the panitumumabþBSC group compared with 1.1 weeks for the
BSC alone treatment group (P¼0.0006); however, patients on
panitumumabþBSC spent 13.3 weeks in the TWiST state
compared with 8.0 weeks for patients on BSC alone and the
difference of 5.3 weeks was statistically significant (Po0.0001).
Patients on BSC alone had a longer duration during REL; however,
the duration of REL for BSC alone was confounded by the cross-
over design of the trial.
Q-TWiST analysis
Applying the utility values from Table 1 to the duration of the TOX
and TWiST states, the quality-adjusted difference between groups
in PFS was 6.5 weeks favouring panitumumabþBSC over BSC
alone (12.3 vs 5.8 weeks, respectively), which was statistically
significant (Po0.0001) (Figure 2). Following incorporation of the
REL state into the calculation, overall Q-TWiST was 18.2 weeks for
panitumumabþBSC compared with 16.1 weeks for BSC alone.
Despite the fact that the duration of the REL state was confounded
by the significant degree of cross-over to panitumumab after
disease progression in those patients randomised to BSC alone
arm, the difference in Q-TWiST between groups (panitumu-
mabþBSC vs BSC alone) was statistically significant (P¼0.0303)
with a point estimate of 2.1 weeks.
Sensitivity analysis
Using a range of hypothetical utility weights for the TOX and
setting the utility for the REL to zero (i.e., the first five rows in
Table 3), differences in quality-adjusted PFS between the two
treatment groups ranged from 5.3 to 7.6 weeks, favouring
panitumumabþBSC. All these differences were also statistically
significant (Po0.0001).
Using varying hypothetical utility weights for both TOX and
REL health states, the overall Q-TWiST difference between groups
Table 1 Average utility values by health state for patients with wild-type
KRAS tumours receiving panitumumabþBSC or BSC alone, based on the
EQ-5D index
PanitumumabþBSC (n¼124) BSC alone (n¼119)
Health state n Utility n Utility
TOX 37 0.6008 13 0.4409
TWiST 104 0.7678 103 0.6630
REL 68 0.6318 63 0.6407
Abbreviations: BSC¼best supportive care; EQ-5D¼EuroQol-5 dimensions;
REL¼relapse period until death or end of follow-up; TOX¼days with Xgrade 3
adverse events; TWiST¼time without symptoms or toxicity.
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Figure 1 Partitioned survival curves for (A) panitumumabþBSC and
(B) BSC alone. BSC¼best supportive care; REL¼relapse period until
death or end of follow up; TOX¼days with Xgrade 3 adverse events;
TWiST¼time without symptoms or toxicity.
Table 2 Mean duration of health states for patients with wild-type KRAS
tumours receiving panitumumab+BSC or BSC alone
Mean duration (weeks)
Health
state
Panitumumab+BSC
(n¼124)
BSC alone
(n¼119)
Difference
(Panit+BSC)
vs BSC P4|Z|
a
TOX 3.47 1.09 2.37 0.0006
TWiST 13.26 8.01 5.25 o0.0001
REL 9.35 16.15  6.80 o0.0001
Abbreviations: BSC¼best supportive care; Panit¼panitumumab; REL¼relapse
period until death or end of follow-up; TOX¼days with Xgrade 3 adverse events;
TWiST¼time without symptoms or toxicity.
aNull hypothesis: difference (panitu-
mumab+BSC – BSC alone)¼0.
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sranged from  1.6 to 7.6 weeks and favoured panitumumabþBSC
therapy for 22 of 25 (or 88% of possible value combinations)
hypothetical utility levels (Table 3; Figure 3). Results were
statistically significant for all TOX utility levels when REL was
valued at p0.5 except utility of TOX¼0 and REL¼0.5.
DISCUSSION
The major goals of treatment for mCRC are prolongation of
survival, improvement of tumour-related symptoms, prevention of
tumour progression and/or maintenance of quality of life (Van
Cutsem et al, 2010). In chemo-refractory wild-type KRAS mCRC,
panitumumabþBSC provided statistically significant improve-
ments in PFS compared with BSC alone (hazard ratio, 0.45; 95% CI:
0.34–0.59) (Amado et al, 2008). However, as dermatological
toxicity is a well-known side effect of anti-EGFR monoclonal
antibodies, including panitumumab (Li and Perez-Soler, 2009), we
considered that it would be particularly valuable to apply the
Q-TWiST analysis to these results, thus combining efficacy and
safety measures, and allowing a direct evaluation of the impact of
treatment toxicities on patient experience (Goldhirsch et al, 1989;
Glasziou et al, 1990; Gelber et al, 1995a; Cole et al, 2004).
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Figure 2 (A) Mean quality-adjusted PFS for patients with wild-type KRAS
mCRC receiving panitumumabþBSC or BSC alone. (B) Mean quality-
adjusted OS for patients with wild-type KRAS mCRC receiving panitumu-
mabþBSC or BSC alone. BSC¼best supportive care; mCRC¼metastatic
colorectal cancer; OS¼overall survival; PFS¼progression-free survival;
Q-TWiST¼quality-adjusted time without symptoms of disease or toxicity
of treatment.
Table 3 Duration and significance of differences between the
panitumumab+BSC and BSC alone groups in Q-TWiST at varying utility
weights
Utility per phase Panitumumab+BSC vs BSC alone
TOX TWiST REL
Difference in
Q-TWiST (weeks) P-value 95% CI
0.00 1.00 0.00 5.25 o0.0001 2.90, 7.59
0.25 1.00 0.00 5.84 o0.0001 3.55, 8.13
0.50 1.00 0.00 6.43 o0.0001 4.15, 8.72
0.75 1.00 0.00 7.03 o0.0001 4.70, 9.36
1.00 1.00 0.00 7.62 o0.0001 5.20, 10.04
0.00 1.00 0.25 3.55 0.0020 1.30, 5.80
0.25 1.00 0.25 4.14 0.0002 1.97, 6.31
0.50 1.00 0.25 4.73 o0.0001 2.60, 6.87
0.75 1.00 0.25 5.33 o0.0001 3.17, 7.48
1.00 1.00 0.25 5.92 o0.0001 3.69, 8.15
0.00 1.00 0.50 1.84 0.1205  0.48, 4.17
0.25 1.00 0.50 2.44 0.0316 0.21, 4.66
0.50 1.00 0.50 3.03 0.0061 0.86, 5.20
0.75 1.00 0.50 3.63 0.0010 1.46, 5.79
1.00 1.00 0.50 4.22 0.0002 2.01, 6.43
0.00 1.00 0.75 0.14 0.9124  2.42, 2.71
0.25 1.00 0.75 0.74 0.5548  1.71, 3.19
0.50 1.00 0.75 1.33 0.2716  1.04, 3.70
0.75 1.00 0.75 1.92 0.1076  0.42, 4.27
1.00 1.00 0.75 2.52 0.0369 0.15, 4.88
0.00 1.00 1.00  1.56 0.2964  4.48, 1.37
0.25 1.00 1.00  0.96 0.5001  3.76, 1.84
0.50 1.00 1.00  0.37 0.7895  3.08, 2.34
0.75 1.00 1.00 0.22 0.8693  2.44, 2.89
1.00 1.00 1.00 0.82 0.5476  1.85, 3.48
Abbreviations: BSC¼best supportive care; Q-TWiST¼quality-adjusted time with-
out symptoms of disease or toxicity of treatment; REL¼relapse period until death or
end of follow-up; TOX¼days with Xgrade 3 adverse events; TWiST¼time without
symptoms or toxicity.
1.0
0.8
+7
+6
+5
+4
+3
+2
+1
0
–1
0.6
0.4
U
t
i
l
i
t
y
 
f
o
r
 
t
o
x
i
c
i
t
y
0.2
0.2
P>0.1 0.05<P<0.10 P<0.5
0.4 0.6
Utility for relapse
0.8 1.0
0.0
0.0
Figure 3 Threshold utility plot showing differences in Q-TWiST
(in weeks) at varying utility levels. Note: Positive numbers indicate a
longer duration of Q-TWiST for patients in combination therapy
(panitumumabþBSC).
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collected during the phase 3 study, patients with wild-type KRAS
tumours receiving panitumumabþBSC compared with patients
on BSC alone had 6.5 more quality-adjusted weeks for PFS. These
results closely reflect the difference in unadjusted PFS reported by
Amado et al (2008), but extend our understanding to suggest that
toxicities associated with panitumumab, such as dermatological
events, are more than offset by the significantly extended time in
the TWiST state compared with BSC alone. We focused on the
period prior to progression, that is PFS, because of the inherent
limitations of the phase 3 study design, which allowed patients
randomised to BSC alone arm to cross over to panitumumab after
disease progression (Van Cutsem et al, 2007). However, despite
these limitations, a difference in overall quality-adjusted survival
between arms was identified. Although relatively small, this
difference was also statistically significant in favour of panitumu-
mabþBSC. The evaluation of a clinically important difference for
Q-TWiST has been studied (Revicki et al, 2006). Based on an
analysis of Q-TWiST studies in oncology, it was recommended that
a Q-TWiST difference of 10% or more be considered clinically
important, with differences of 15% or more being clearly clinically
important. In the current study, the differences in quality-adjusted
PFS between the two treatment groups ranged from 5.3 to 7.6
weeks longer for panitumumabþBSC compared with BSC alone,
representing a 73–104% increase in the median PFS of 7.3 weeks
seen in the BSC alone arm (Amado et al, 2008). These values would
be considered clearly clinically important according to Revicki
et al (2006). Despite the significance of the relative difference,
however, the absolute improvement was rather modest.
In the primary analysis, we used utility scores based on actual
EQ-5D assessments made during this study. We noted that EQ-5D
scores were higher for patients on panitumumabþBSC compared
with patients on BSC alone during periods of both TOX and
TWiST, which is supported by the demonstration of better
maintenance of overall HRQoL in patients on panitumumabþBSC
compared with BSC alone (Odom et al, 2011). The most frequent
toxicity of panitumumab is skin rash (Van Cutsem et al, 2007).
Despite the perceived detrimental impact of skin rash on HRQoL
(Lynch et al, 2007), the higher EQ-5D during periods of TOX in
patients on panitumumabþBSC is consistent with the reported
association between more severe skin toxicity and higher rather than
lower HRQoL scores (Peeters et al, 2009). More severe skin toxicity
following panitumumab treatment has been also associated with
improved outcomes (Peeters et al, 2009; Douillard et al, 2010).
Basing quality adjustments on patients’ experience of the
treatments administered during the clinical trial is a strength of
this analysis in that it does reflect the actual utilities obtained.
There are also associated limitations, as EQ-5D scores were not
reported for all patients or all visits. However, we performed a
sensitivity analysis to assess anticipated Q-TWiST differences
across of range of possible utilities – an approach that is often used
as the core method in Q-TWiST analyses reported in the literature
(Gelber et al, 1996; Irish et al, 2005; Konski et al, 2009). This
analysis provides an assessment of how patient preferences for
trade-offs in disease control compared with tolerability concerns
might influence treatment choice. Varying the utility weight for the
TOX state between 0 and 1 consistently showed that the quality-
adjusted PFS for panitumumabþBSC was significantly longer
than that of the BSC alone arm. Similar sensitivity analyses were
also performed for overall quality-adjusted survival. Since the
utility for the REL state determined from the clinical trial data was
based on EQ-5D values at withdrawal (or was censored if these
data were unavailable), these values may not reflect realistic values
for the entire period after disease progression during which
significant deterioration in health is anticipated. In the threshold
utility analysis, panitumumabþBSC therapy was favoured over
BSC alone for most of the hypothetical utility levels applied to the
Q-TWiST calculations. As shown in Table 3, the most pronounced
differences favouring panitumumab treatment were seen when the
REL state was valued at low levels. However, the gain for using
panitumumab decreased as the utility weights for REL increased
(40.5), especially as the utility weights of time in TOX also decreased.
It is worthwhile to note that this Q-TWiST analysis was based on
primary PFS data that demonstrated a significant improvement in
PFS for panitumumabþBSC over BSC alone. A greater improve-
ment in PFS was seen for panitumumabþBSC vs BSC alone based
on the PFS analysis by the Committee for Medicinal Products for
Human Use, in which unscheduled tumour assessments were
moved to the nearest scheduled time point. Thus, if a Q-TWiST
analysis was based on the latter PFS, we would likely expect a
larger advantage in quality-adjusted PFS. Also, since the period of
REL, and thus the OS, was confounded by the cross-over design
of the trial, it was likely the quality-adjusted OS benefit of
panitumumab derived from this Q-TWiST analysis might under-
estimate the true OS benefit of panitumumab.
Quality-adjusted time without symptoms of disease or toxicity
of treatment can be considered as an alternative to the quality-
adjusted life years (QALY), which is the most established method
of combining quality and quantity of life used extensively in cost-
effectiveness analysis (Miyamoto and Eraker, 1985; Miyamoto,
1999). In Q-TWiST analysis, utility scores are assigned to a
number of discrete pre-defined ‘states’ (such as TOX, REL) that
each patient may experience, which allows flexibility on a study-
by-study basis. However, of course, this generates inconsistencies
between studies and so, unlike QALYs, it is impossible to compare
across studies or disease groups unless exactly the same scheme is
used. There are also frequently concerns about the selection of
Q-TWiST states and utilities, particularly for the latter, which may
be very arbitrary and often questionable. Nevertheless, the
Q-TWIST concept is an innovative method of adjusting survival
to account for different patient experiences, and can be based on
clinical information, and calculated without prospective ques-
tionnaires. To mitigate concerns regarding the selection of utilities,
sensitivity analyses were conducted based on the threshold utility
analyses as described in the literature (Goldhirsch et al, 1989;
Gelber et al, 1995b; Cole et al, 1996). Some additional limitations of
the study also need to be acknowledged. First, the study followed
the standard approach of the Q-TWiST analysis, in which only
grade 3 or 4 AEs were taken into considered in the calculation of
the TOX period. However, a sensitivity analysis that incorporated
grade 2 AEs was conducted and consistent findings were observed
(data not shown). Second, for the TOX period, a day with multiple
AEs was only counted once and AEs were not differentiated based
on their types. Third, in the primary analysis, patient-reported
EQ-5D data were used to derive utility weights. Ideally, EQ-5D
should have been assessed daily, so the utility weights could be
derived from all days when AEs were being experienced. In fact,
EQ-5D was not reported by all patients at all visits (Odom et al,
2011) and was assessed only monthly. Despite these limitations,
the estimated utility values for different states (TOX, TWiST or
REL) were in the range as reported in the literature (Earle et al,
2000; Sherrill et al, 2008), and the difference between panitumu-
mabþBSC vs BSC alone was also consistent with the overall better
HRQoL as measured by EQ-5D reported by Odom et al (2011).
In conclusion, in patients with wild-type KRAS mCRC, panitumumab
þBSC provided significant improvements in quality-adjusted PFS
and quality-adjusted OS compared with BSC alone, illustrating that
the toxicities associated with panitumumab are more than offset by
the associated increase in time without severe toxicity.
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